Sponsored Links 
Top Health Equity Funds
Print
ShareToday we are featuring top-performing “Health" equity mutual funds, which primarily invest in equity securities of healthcare and related companies.
Investors can find such funds by checking out the entire list of the Zacks #1 Rank Health Equity Funds.
3 Healthy Picks
BlackRock Health Sciences Opps A (SHSAX) seeks to provide long-term growth of capital. It was incepted in December 1999.
The fund invests at least 80% of its total assets in securities of companies in health sciences and related industries. Its investments may include common and preferred stocks, convertible securities, warrants and depository receipts. The fund reserves the right to invest up to 20% of its total assets in other securities. These may include stocks of companies not associated with health sciences.
The fund has an expense ratio of 1.43%. As of June 2009, it has a portfolio turnover of 144%.
Thomas P. Callan has been lead manager of the fund since January 2005. Callan is a Chartered Financial Analyst and managing director at BlackRock and heads the firm’s Global Opportunities equity team.
Vanguard Health Care Inv (VGHCX) seeks long-term growth of capital and dividend income. It was incepted in May 1984.
The fund invests in common stocks of companies in a variety of segments of the health-care industry. Its selections may include pharmaceutical firms, designers and manufacturers of medical equipment and supplies, operators of hospitals and other health-care facilities, and biotechnological researchers. The fund seeks a balanced representation of the industry.
The fund distributes dividends and capital gains annually in December. It has an expense ratio of 0.29%.
Edward P. Owens has been lead manager of the fund since May 1984. Owens has over 32 years of experience at Wellington Management, Vanguard Wellington Funds advisor and is a portfolio manager for the Health Care sector at the firm.
Fidelity Select Biotechnology (FBIOX) was incepted in December 1985. The objective of this fund is to seek capital appreciation.
The fund normally invests at least 80% of assets in common stocks of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. It may invest in securities of foreign issuers. The fund is non-diversified.
Shareholders have to make a minimum initial investment of $2,500 to enter this Zacks #1 Rank ("Strong Buy") fund. It has an expense ratio of 0. 89%.
Rajiv Kaul has been lead manager of the fund since October 2005. Kaul has been with Fidelity Investments since 1996 and is a portfolio manager with the firm.
Discover Many More Funds
Learn more about the new Zacks Mutual Fund Rank and discover some of the best market-beating mutual funds by browsing our mutual funds section. This part of Zacks.com offers a variety of tools, including mutual fund research, a new mutual fund screener, helpful answers to frequently asked questions and quick access to prospectuses and other information.
By applying the Zacks Rank to mutual funds, investors can find funds that not only outpaced the market in the past but are also expected to outperform going forward.
Read the full analyst report on SHSAX
Read the full analyst report on VGHCX
Read the full analyst report on FBIOX
Loading Stories...
-0.23 %
More Zacks Resources
More Zacks Links
| Market Summary | Feb 10, 2012 18:59 pm ET |